Countries in transition – The challenges of middle-income countries 18 July 2016 AIDS 2016 in Durban, South Africa Sumet Ongwandee, MD MS MPH Bureau of.

Slides:



Advertisements
Similar presentations
Scaling up ART in Sénégal: specifics needs for strategic information Mame Awa Toure MD, MSc AIDS/STI Division, MOH Senegal.
Advertisements

Reducing impoverishment from health payments: impact of universal health care coverage in Thailand Phusit Prakongsai 1 Supon Limwattananon 1,2 Viroj Tangcharoensathien.
ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.
Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.
Assessing the impact of a policy on universal coverage on financial risk protection, health care finance, and benefit incidence of the Thai health care.
Health Care Delivery and Referral System in Thailand
“Getting to Zero: Thailand’s Experience with E-MTCT” Petchsri Sirinirund Advisor on HIV/AIDS Policy and Programme Department of Disease Control, Thailand.
Methods for Estimating Global Resource Needs for HIV/AIDS John Stover, Lori Bollinger International AIDS Economic Network Meeting, Washington,
Payment methods of health insurance system in Thailand
National ART Program - NAP Utilization of NAP Monitoring data for Policy Decision “Treatment as Prevention” Sorakij Bhakeecheep, MD Director National Health.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
Kevin Fenton, MD, PhD, FFPH Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention.
Essential Medicines Programmes Sudan now Essential Medicines Programmes Sudan now.
HIV in Suriname Ministry of Health Suriname M.Sigrid Mac Donald – Ottevanger, MD Focal point HIV Treatment and Care, NAP.
Challenges to universal health coverage in Thailand
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
Current status, problems, and challenges in public health in Thailand Dr. Phusit Prakongsai, MD. Ph.D. International Health Policy Program – IHPP Ministry.
Health care system In Thailand.
International Health Policy Program -Thailand The 3 rd Global Symposium on Health Systems Research Cape Town International Convention Center, Cape Town,
Group Discussion Guyana, The Bahamas T & T, Jamaica Barbados, Haiti Suriname, Curacao.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Sombat Thanprasertsuk MD, MPH Department of Disease Control, MOPH Thailand 2 July 2013.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
International Health Policy Program -Thailand Financing for Universal Coverage Experiences from Thailand Phusit Prakongsai, M.D. Ph.D. Viroj Tangcharoensathien,
Ministry of Healthcare & Nutrition Broader Approaches to Health Strategic Frame Work for Health Development.
1 Health insurance system in Mongolia Ch. Oyun, MD, MPH.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
Evaluating ten years of universal health coverage in Thailand Viroj Tangcharoensathien, MD. Ph.D. Phusit Prakongsai, MD. Ph.D. International Health Policy.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Ministry of Public Health & Population Haiti Toward Universal Care HIV/AIDS October 2010.
Sharing Innovative Experiences on Social Protection Floor: Case Studies From Thailand ITC, Turin, Italy 8-9 July 2010 Worawet Suwanrada Faculty of Economics.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
Health Care Financing Health Economic Course Series
1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.
Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.
ACTIVITY-BASED COSTING (ABC)
Lessons from Thailand in achieving universal health coverage: Contributing factors and key challenges Phusit Prakongsai, MD. Ph.D. Director of Bureau.
Development of NAPHA in Thailand
ILO Programme on HIV and AIDS and the world of work,
Peeramon Ningsanond MD. Bureau of AIDS TB STI, DDC, MOPH Thailand
Nevenka Mardešić, NGO HELP, Croatia
Facilitating development and adaptation of the right tools
Zimbabwe’s shift towards treat all: national country context
Current harm reduction program at outreach
Transition process from Global Fond to domestic funding in Croatia
Expanding ARV treatment in developing countries: Issues and Prospects
The Debswana Anti Retroviral Therapy Programme
Utilizing research as an opportunity to strengthen
Access to ARV : Non Rational ... Approach to Inappropriate Treatment
Building Health Systems to Deliver People-centered Health Services
Training Seminar on Social Security
HIV Quality Improvement (QI) and the Treatment Cascade: How QI has Impacted Reach, Recruitment, Testing, Treatment, and Retention Efforts in Thailand?
Thokozani Kalua MBBS MSc Malawi Ministry of Health
22nd International AIDS Conference Amsterdam, 24 July 2018
EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.
Nittaya Phanuphak, MD, PhD 
Serge Masyn Director, Johnson & Johnson Global Public Health
Enablers for nationwide expansion of collaborative TB/HIV activities
DECREASES DONOR FUNDING WHAT SHALL BE DONE IF TO FIGHT HIV DRASTICALLY
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
Petchsri Sirinirund Advisor to HIV/AIDS Policy and Programme
Vietnam Investment and Finance for TB
Health system assessments
Fabio Scano IUATLD Conference Paris, 2003
How can we make healthcare purchasing in Kenya more strategic?
A pathway to policy commitment for sustainability of a key population-led health services model in Thailand Dr. Preecha Prempree Deputy Director-General,
Presentation transcript:

Countries in transition – The challenges of middle-income countries 18 July 2016 AIDS 2016 in Durban, South Africa Sumet Ongwandee, MD MS MPH Bureau of AIDS TB and STI Department of Disease Control

Current Social Health Protection Schemes Social health protection schemes have covered all Thai citizen since 2002 Major Schemes Civil Servant Medical Benefit Scheme (CSMBS) Social Security Scheme (SSS) Universal Coverage (UCS) Introduced in 1960s 1990s 2002 Target beneficiaries Government employees & dependents, retirees Private sector employees: To whom which not covered by CSMBS nor SSS, Pop. Coverage 7% 16% 75% Funding Government budget (Tax) Payroll contribution, Tripartite (Social Health Insurance) Payment to health facilities Fee-for-service for OP, DRG for IP Capitation for OP & IP, DRG for Adjusted RW >= 2 Capitation for OP, DRG for IP Source: Dr. Thaworn Sakunphanit, Health Insurance Research Office

ART Scaling up: Past and Present 1984 Firstly reported case of AIDS 1992 AZT mono therapy 1995 Double nucleoside regimens 2000 HAART under Access to Care project or NAPHA 2002 Fixed dose combination “GPO Vir”, Big cost reduction 2005 MOPH started transferring NAPHA to NHSO In 1992, the National AIDS committee launched the national policy to subsidize the provision of ARV for free of charge to people. It was AZT monotherapy that could cover 150 patients in that year. In 1995, the regimen was changed to double therapy, the combination of AZT+ddI or AZT+ddC. In that year, the central supply also included OI drugs and free condom to distribute. In 2000, the MOPH initiated the concept of Access to care by implementing the principles of equal accessibility to Highly Active Anti-Retroviral therapy (HAART), besides free ARV, there were the improvement of quality services, a holistic care. The program also included PLWHA and community to involve in the process of HIV care. In 2002, this was the great year that Thai GPO can produce a fixed dose combination or GPO vir (a combination of d4T, 3TC, NVP). The cost of ARV was down in great number and the country can scale up more people under treatment from 1,700 to 13,000 in the year later. In 2004, it was a year that the government fully committed itself to provide ARV for all Thai PLWHA. The MOPH had transferred the NAPHA program to the NHSO which was established in 2000. However, it was until 2006 that the NHSO could fully function the National AIDS program nation-wide. Introduction of ARVs and enhancing health facilities capacity to provide services nationwide under research project Launched national access to ART program by MOPH with partly supported by GF NHSO was established in 2003. Not until 2006, NHSO has completely adopted ART program and scaled up nationwide ART = Anti-Retroviral Therapy NHSO = National Health Security Office GPO = Government Pharmaceutical Organization NAPHA = National Access to Antiretroviral Program for People living with HIV/AIDS MOPH changed GF support to ART program for non-Thais

Source: National AIDS Spending Assessment, National AIDS Management Center

Thailand’s ART Situation (2015) Estimated all PLHIV 438,100 Current PLHIV Diagnosed 391,484 # PLHIV in care 376,987 # receiving ART 283,747 # VL suppression 215,058 ARV clinic 1,086 CD4 Lab 120 Viral load Lab 45 Genotype Lab 14 PCR Lab 16 Demands Supplies Average newly ARV initiation before 2014 24,000 Average newly ART initiation after 2014 32,000 Source: Adapted from Dr. Sorakij’s presentation at ATFOA meeting in Mandalay, Myanmar, 2014

ART Program Budget under UHC (2007-2013) This graph shows the number of PWHA and budget of ART program in UHC The number of PWHA is increasing over time. While the number of PWHA receiving ART increase more than 2.7 times since implementation, average ART program budget remains stable at around 100 mUSD. 58%  ARV cost 27%  LAB cost 99%  Domestic governmental fund 1%  Global Fund ART program budget under UHC ran steadily around 100 mUSD for years. Source: Adapted from Dr. Sorakij’s presentation at ATFOA meeting in Mandalay, Myanmar, 2014

Unit cost of ARV per year (First & second line) Central procurement and compulsory licensing are important mechanisms in controlling ARV prices. Second line ARV Compulsory licensing on EFV, LPV/Ritonavir Global ARV price continues to drop significantly The major components of ART budget is ARV drugs. In Thailand, about 75% of ART program contributes to ARV drugs, 20% to lab, and the rest 5% to others. Normally, the global ARV prices itself continue to drop gradually. As a result of Thailand’s compulsory licensing on EFV and Lopinavir+Ritonavir, cost of ARV falls dramatically. Average unit cost of first and second line ARV falls to nearly 50% during past 5 years. Accordingly, central procurement and compulsory licensing are the most important mechanisms in controlling ARV prices. First line ARV Average unit cost of first and second line ARV falls to nearly 50% during past 5 years. Source: Adapted from Dr. Sorakij’s presentation at ATFOA meeting in Mandalay, Myanmar, 2014

Thailand’s unit cost for ART Program Items Unit cost $/pt/yr I. Drugs ARV for Rx 280 Lipid drugs 3.1 II. LAB Basic lab 5.7 CD4 21.4 Viral load 36.7 Drug resistance 5.6 Total (Drugs + Lab) 352.5 In 2013, the average unit cost of ART program, including drugs and lab, is 352 USD/yr or less than 1 USD/day *price in 2014 Approx. 1$ /pt/day Source: Adapted from Dr. Sorakij’s presentation at ATFOA meeting in Mandalay, Myanmar, 2014

Key components to UHC in ART Program Standard ART service package: ARVs, regimens, lab test ARV procurement and logistics system: central procurement, VMI Financial mechanism: reimbursement system Health system strengthening: a network of HIV experts, training program for health personnel, quality improvement program Community involvement: Day care center Management information system: NAP electronic data system Monitoring and Evaluation, CQI, HIVDR surveillance Universal access to ART program is a public health service aiming to provide comprehensive, equitable and quality access to essential treatment for PLHIV

Acknowledgement National Health Security Office Thai-US Collaboration/US-CDC National AIDS Management Center Thai Network of PLHIV (TNP+)